Integra LifeSciences (IART) Misses Q3 EPS by 2c; Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wells Fargo Downgrades Integra LifeSciences (IART) to Market Perform
October 30, 2017 12:29 AM EDTWells Fargo downgraded Integra LifeSciences (NASDAQ: IART) from Outperform to Market Perform with a price target of $46.00.
The analyst believes the company organic growth will come in below the industry average over the coming 12 months on the heels of fresh competition, the acquisition... More
JPMorgan Downgrades Integra LifeSciences (IART) to Neutral
October 27, 2017 4:41 AM EDTJPMorgan downgraded Integra LifeSciences (NASDAQ: IART) from Overweight to Neutral with a price target of $44.00 (from $58.00).
Analyst Robbie Marcus cites a deteriorating base business and lowered growth outlook for the downgrade. The analyst fails to see a justification for a premium anymore noting growth degradation... More
